Will Recent Major Trials With CDK Inhibitors Be Practice Changing In Early Breast Cancer?
Speakers
Programme
Time |
Title |
Speaker |
|---|---|---|
5 |
Welcome and Introduction |
Giuseppe Curigliano, University of Milano, Istituto Europeo di Oncologia, Milan, Italy |
10 |
Risk Stratification in ER-positive/HER2-negative Early Breast Cancer: Pathological, Clinical and Genomic Risk |
Lajos Pusztai, Yale Cancer Center, Yale School of Medicine, New Haven, CT, US |
15 |
The Impact of CDK 4-6 Inhibitors in the Adjuvant Treatment of ER-positive/HER2-negative High Risk Breast Cancer |
Hope Rugo, Division of Hematology and Oncology, University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, US |
20 |
Omission of Chemotherapy in the Adjuvant Setting: Optimising Treatment by Risk Stratification |
Giuseppe Curigliano, University of Milano, Istituto Europeo di Oncologia, Milan, Italy |
25 |
What Have We Learned From Neoadjuvant CDK4/6 Inhibitor Trials and What Will We Plan for the Future in eBC? |
Sibylle Loibl, GBG Forschungs GmbH, Academic Research Organisation (ARO), Neu-Isenburg, Germany |
30 |
Q&A |
|
35 |
Closing Remarks |
Giuseppe Curigliano, University of Milano, Istituto Europeo di Oncologia, Milan, Italy |
Learning objectives
- Understand the impact of CDK 4-6 inhibitors in the adjuvant therapy of breast cancer
- Learn how to perform a risk assessment in ER-positive/HER2-negative early breast cancer and how to define risk stratification
- Redefine treatment selection and prioritisation in the adjuvant setting
- Contextualise the results of the neoadjuvant trials with CDK 4-6 inhibitors in early breast cancer